We're covering the topic on everyone’s minds—coronavirus. We’ll start with the state of the epidemic as it relates to patients with cancer and the preparedness of the institutions that care for them. Next, we’ll look at a study from China that examined the impact of COVID-19 on patients with cancer. Then, we’ll finish up by discussing an FDA approval of a combination therapy for patients with hepatocellular carcinoma.
Coverage of stories discussed this week on ascopost.com:
Mitigating the Spread of COVID-19 and Its Impact on Cancer
COVID-19 Infection in Patients With Cancer in China
FDA Approves Nivolumab/Ipilimumab for Pretreated Patients With Hepatocellular Carcinoma
We're covering the topic on everyone’s minds—coronavirus. We’ll start with the state of the epidemic as it relates to patients with cancer and the preparedness of the institutions that care for them. Next, we’ll look at a study from China that examined the impact of COVID-19 on patients with cancer. Then, we’ll finish up by discussing an FDA approval of a combination therapy for patients with hepatocellular carcinoma.
Coverage of stories discussed this week on ascopost.com:
Mitigating the Spread of COVID-19 and Its Impact on Cancer
COVID-19 Infection in Patients With Cancer in China
FDA Approves Nivolumab/Ipilimumab for Pretreated Patients With Hepatocellular Carcinoma
We're covering the topic on everyone’s minds—coronavirus. We’ll start with the state of the epidemic as it relates to patients with cancer and the preparedness of the institutions that care for them. Next, we’ll look at a study from China that examined the impact of COVID-19 on patients with cancer. Then, we’ll finish up by discussing an FDA approval of a combination therapy for patients with hepatocellular carcinoma.
Coverage of stories discussed this week on ascopost.com:
Mitigating the Spread of COVID-19 and Its Impact on Cancer
COVID-19 Infection in Patients With Cancer in China
FDA Approves Nivolumab/Ipilimumab for Pretreated Patients With Hepatocellular Carcinoma
We're covering the topic on everyone’s minds—coronavirus. We’ll start with the state of the epidemic as it relates to patients with cancer and the preparedness of the institutions that care for them. Next, we’ll look at a study from China that examined the impact of COVID-19 on patients with cancer. Then, we’ll finish up by discussing an FDA approval of a combination therapy for patients with hepatocellular carcinoma.
Coverage of stories discussed this week on ascopost.com:
Mitigating the Spread of COVID-19 and Its Impact on Cancer
COVID-19 Infection in Patients With Cancer in China
FDA Approves Nivolumab/Ipilimumab for Pretreated Patients With Hepatocellular Carcinoma
We're covering the topic on everyone’s minds—coronavirus. We’ll start with the state of the epidemic as it relates to patients with cancer and the preparedness of the institutions that care for them. Next, we’ll look at a study from China that examined the impact of COVID-19 on patients with cancer. Then, we’ll finish up by discussing an FDA approval of a combination therapy for patients with hepatocellular carcinoma.
Coverage of stories discussed this week on ascopost.com:
Mitigating the Spread of COVID-19 and Its Impact on Cancer
COVID-19 Infection in Patients With Cancer in China
FDA Approves Nivolumab/Ipilimumab for Pretreated Patients With Hepatocellular Carcinoma